Envestnet Asset Management
VKTX icon

Envestnet Asset Management’s Viking Therapeutics VKTX Stock Holding History

Envestnet Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.59M Buy
66,369
+6,259
+10% +$202K ﹤0.01% 2958
2026
Q1 		$1.96M Buy
60,110
+13,729
+30% +$441K ﹤0.01% 3029
2025
Q4 		$1.63M Sell
46,381
-28,670
-38% -$1.02M ﹤0.01% 2976
2025
Q3 		$1.97M Buy
75,051
+1,792
+2% +$53.5K ﹤0.01% 2889
2025
Q2 		$1.94M Buy
73,259
+25,120
+52% +$661K ﹤0.01% 2845
2025
Q1 		$1.16M Buy
48,139
+6,294
+15% +$199K ﹤0.01% 3107
2024
Q4 		$1.68M Sell
41,845
-9,382
-18% -$535K ﹤0.01% 2812
2024
Q3 		$3.24M Buy
51,227
+30,873
+152% +$1.81M ﹤0.01% 2370
2024
Q2 		$1.08M Buy
20,354
+675
+3% +$44.2K ﹤0.01% 2989
2024
Q1 		$1.61M Buy
+19,679
New +$876K ﹤0.01% 2707
2023
Q3 		– Sell
-16,626
Closed -$270K – 4169
2023
Q2 		$270K Sell
16,626
-948
-5% -$19.9K ﹤0.01% 3542
2023
Q1 		$293K Buy
17,574
+2,283
+15% +$23.6K ﹤0.01% 3451
2022
Q4 		$144K Sell
15,291
-1,091
-7% -$4.87K ﹤0.01% 3742
2022
Q3 		$45K Sell
16,382
-1,974
-11% -$6.46K ﹤0.01% 3815
2022
Q2 		$53K Buy
+18,356
New +$45.4K ﹤0.01% 3814
2021
Q4 		– Sell
-31,050
Closed -$195K – 3953
2021
Q3 		$195K Buy
31,050
+1,417
+5% +$8.75K ﹤0.01% 3510
2021
Q2 		$178K Buy
29,633
+677
+2% +$4.02K ﹤0.01% 3511
2021
Q1 		$183K Buy
28,956
+8,659
+43% +$60.9K ﹤0.01% 3363
2020
Q4 		$114K Sell
20,297
-8,033
-28% -$48.7K ﹤0.01% 3195
2020
Q3 		$165K Sell
28,330
-3,492
-11% -$24K ﹤0.01% 2956
2020
Q2 		$229K Sell
31,822
-7,826
-20% -$52K ﹤0.01% 2818
2020
Q1 		$186K Sell
39,648
-446
-1% -$2.74K ﹤0.01% 2751
2019
Q4 		$322K Buy
40,094
+1,885
+5% +$13.7K ﹤0.01% 2697
2019
Q3 		$263K Sell
38,209
-478
-1% -$3.55K ﹤0.01% 2732
2019
Q2 		$321K Buy
38,687
+1,427
+4% +$12.2K ﹤0.01% 2623
2019
Q1 		$370K Buy
37,260
+15,125
+68% +$127K ﹤0.01% 2502
2018
Q4 		$169K Buy
+22,135
New +$265K ﹤0.01% 2730

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Envestnet Asset Management's VKTX Position: Q2 2026 in Review

Envestnet Asset Management increased its Viking Therapeutics (VKTX) stake by 10% in Q2 2026, buying an estimated $202K and bringing the position to 66,369 shares worth $2.59M. The position accounts for ﹤0.01% of the portfolio, ranked #2958.

Envestnet Asset Management first reported a position in VKTX in Q4 2018 and has held it in 27 quarters since. The position peaked at $3.24M in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Envestnet Asset Management held 66,369 shares of Viking Therapeutics worth $2.59M as of Q2 2026.
  • Envestnet Asset Management bought 6,259 Viking Therapeutics shares in Q2 2026, an estimated $202K.
  • Viking Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #2958 holding.
  • Envestnet Asset Management first reported a position in Viking Therapeutics in Q4 2018 and has held it in 27 quarters since.
  • Envestnet Asset Management's Viking Therapeutics position peaked at $3.24M in Q3 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.